Encapsulation of N-acetylmuramyl-L-a-aminobutyryl-D-isoglutamine in multilamellar vesicles composed of phosphatidylcholine, cholesterol, and phosphatidylserine (7:6.7:3) or phosphatidylcholine and phosphatidylserine (7:3) reduced the amount of drug needed to protect against a Candida albicans intravenous infection. The 50% effective doses for encapsulated and free drug were 5.5 and >80 mg/kg, respectively. The optimum treatment was twice (at days 4 and 2 preinfection) by the intravenous route. Intraperitoneal, subcutaneous, and oral routes of administration were ineffective. The same potentiation of anti-Candida activity was observed whether the lower dose of drug was encapsulated in multilamellar vesicles, mixed with multilamellar vesicles, or given either 1 h before or 1 h after multilamellar vesicles. It was postulated that the mechanism of action involved the retention of the liposomes by organs of the reticuloendothelial system, resulting in an enhanced response of the macrophages to the immunostimulating activity of the N-acetylmuramyl-L-cE-aminobutyryl-D-isoglutamine given in conjunction with the vesicles.
The muramyl dipeptide (MDP) analog N-acetylmuramyl-L-o-aminobutyryl -D-isoglutamine ([Abu1]MDP) was found to cause enhanced resistance against subsequent infection with Candida albicans or Pseudomonas aeruginosa (7, 8) . Relatively high doses of the drug were needed. The response was maximal with four daily preinfection treatments at a dose of 40 mg/kg and became suboptimal at doses around 20 mg/kg. One injection at day 1 or 4 preinfection, regardless of concentration, was not sufficient to provide good antiinfective activity, even when the dose was as high as 320 mg/kg. In view of the fact that MDP is 90% eliminated from the host in 2 h (17), we felt that it might be beneficial to use vesicles to encapsulate [Abut] MDP so that the compound would remain in the host for longer periods of time.
Liposomes have been studied in recent years as a means of improving drug delivery and release. Studies on the distribution of liposomes in vivo have shown that after intravenous (i.v.) administration they are localized in the organs of the reticuloendothelial system (RES), including the spleen and liver (12) . Since MDP has been shown to affect macrophage function both in vitro (1, 9, 11, 14, 15, 21, 23, 24, 26) and in vivo (7, 22, 25) and to increase the size of both the spleen and the lymph nodes (Fraser- (3, 4, 19 C. albicans infection. We used human clinical isolate of C. albicans (Ca 523), which was maintained and prepared as described previously (7) . The challenge dose given to each mouse by the i.v. route was 5 x 106 cells in 0.2 ml of saline. Survivors were recorded for 5 to 10 days; after this time there were no surviving control mice which received saline in MLV-or saline alone.
Quantitation of spleen weight. Spleens were removed from 10 treated mice per group, fixed in Formalin, and weighed 3 days later. These spleens were observed histologically after being sectioned and stained with hematoxylin and eosin. Treatment was by different routes of administration, using different treatment schedules and dose levels, as indicated below. quench corrected to disintegrations per minute. Statistical analysis. Statistical evaluation of differences in survival time between the various treated and control groups was done by using the Mann-Whitney U probability test (10) . All mice which had not died by the time that there were no longer any surviving controls treated with saline in MLV-or saline alone were assigned a survival time of 24 h later for this comparison. Differences in the number of survivors when all controls had died were evaluated by using the Fisher exact probability two-tailed test (13) . P values of <0.05 were considered to be significant.
A t test (20) was used to determine whether there was a significant difference in spleen weight between treated and control animals.
Probit analysis (6) Mixing the glycopeptide and MLV together gave protection as good as that observed when the drug was encapsulated at all dose levels tested ( Fig. 2 and [Abu1]MDP in MLV was 5.5 mg/kg when the MLV-treated controls no longer had any survivors, whereas the ED50 was >80 mg/kg for free [Abu1]MDP in the same test. The fact that a glycopeptide encapsulated in liposomes is more efficient than free glycopeptide in stimulating an immune response has been reported by other workers in different in vivo and in vitro antitumor studies. Injections of MLV containing the parent compound, MDP, into mice significantly decreased the incidence of spontaneous pulmonary metastases of a B16-BL6 melanoma, whereas equivalent doses of free MDP did not (4) . A dose-response experiment established that in vitro, liposome-encapsulated MDP rendered alveolar macrophages tumoricidal at lower concentrations than free MDP in the medium did (19) .
[Abu1]MDP encapsulated in MLV and injected at a level of 2 mg/kg per dose at days 4 and 2 preinfection protected against a C. albicans i.v. infection when the route of administration was i.v., but not when it was i.p. or s.c. By comparison, treatment with free glycopeptide once a day for 4 days at a level of 40 mg/kg per dose gave maximum protection against a C. albicans infection regardless of whether the compound was administered i.v., i.p., or s.c. (7) . No protection was observed with free drug alone by any route when the concentration used was 2 mg/kg per dose.
We attribute the difference in these results to the successful targeting by the i.v. route of administration of MLV to organs of the RES, which apparently potentiates the immunostimulating activity of [Abu1]MDP. Liposomes are mainly taken up by the organs of the RES after i.v. injection, whereas they remain more localized after i.p. or s.c. inoculation and are poorly absorbed (if at all) from the intestine (4, 5, 12, 16 
